Trial Profile
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2017.
- 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.